Published in Transplant Direct on January 11, 2016
Desensitization: Overcoming the Immunologic Barriers to Transplantation. J Immunol Res (2017) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation (2008) 1.84
Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant (2015) 1.72
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int (2014) 1.56
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation (2015) 1.50
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol (2011) 1.40
Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol (2012) 1.21
Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol (1997) 1.11
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation (2013) 1.09
Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation (2003) 1.08
Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol (2008) 1.06
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol (2012) 0.95
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation (2014) 0.93
Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant (2008) 0.89
Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation (2013) 0.87
Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl (2011) 0.83
Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy. Transpl Int (2013) 0.82
Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation (2012) 0.81
Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clin Biochem (2013) 0.80
A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation (2014) 0.79
Questioning the added value of Luminex single antigen beads to detect C1q binding donor HLA-specific antibodies. Transplantation (2014) 0.79
Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure. Transplantation (2015) 0.77